Astrotech Corp (ASTC) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Astrotech Corp (ASTC) stock forecast summary
On Oct. 13, 2026, ASTC is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
Astrotech Corp is a small-cap company with a market capitalization of $11M. It ranks number 24 by market capitalization among the 25 Laboratory Analytical Instruments issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for ASTC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, ASTC included.
Follow ASTC freeASTC price chart and AI forecast
How ASTC ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Astrotech Corp (ASTC) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Laboratory Analytical Instruments peers listed below that report each metric.
Valuation & Market
| Metric | ASTC | Rank |
|---|---|---|
| Market Cap | $11M | 24/25 |
| P/B Ratio | 0.73x | 20/23 |
| Book Value/Share | $8.47 | – |
Profitability & Margins
| Metric | ASTC | Rank |
|---|---|---|
| ROE | -92.3% | 18/21 |
| ROA | -72.8% | 20/22 |
| ROIC | -75.7% | 17/21 |
| Gross Margin | 29.8% | 18/19 |
| Operating Margin | -1220.9% | 20/21 |
| Net Margin | -1319.9% | 19/20 |
| EBT Margin | -2559.1% | 21/22 |
| Tax Rate | -0.0% | – |
Financial Health
| Metric | ASTC | Rank |
|---|---|---|
| Current Ratio | 7.06x | 5/25 |
| Quick Ratio | 6.53x | 4/24 |
| D/E Ratio | 0.27x | 18/24 |
| Financial Leverage | 1.27x | 18/24 |
| Interest Coverage | -1151.0x | 20/21 |
| Working Capital | $14M | 21/25 |
Cash Flow
| Metric | ASTC | Rank |
|---|---|---|
| Operating Cash Flow | -$14M | 17/24 |
Operational Efficiency
| Metric | ASTC | Rank |
|---|---|---|
| Inventory Turnover | 0.5x | 19/19 |
| Days Inventory | 778 days | 1/19 |
| Payables Period | 383 days | 1/18 |
Income Statement
| Metric | ASTC | Rank |
|---|---|---|
| Operating Income | -$13M | 10/21 |
| Net Income | -$14M | 10/22 |
| R&D Expense | $7M | 19/21 |
| SG&A Expense | $7M | 19/20 |
| Cost of Goods Sold | $550K | 19/19 |
Dividend & Shareholder Information
| Metric | ASTC | Rank |
|---|---|---|
| Shares Outstanding | 2M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $16M | 82.9% of assets |
| Cash & Short-term Investments | $8M | 43.7% of assets |
| Accounts Receivable | $120K | 0.6% of assets |
| Inventory | $1M | 6.1% of assets |
| Total Liabilities | $4M | 22.5% of assets |
| Short-term Debt | $2M | 8.7% of assets |
ASTC quarterly financials and insider trading
Astrotech Corp (ASTC) industry peers
Companies classified under the same SEC industry code as Astrotech Corp (Laboratory Analytical Instruments): 25 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| ASTC Astrotech Corp | ▶ | $11M |
| A Agilent Technologies, Inc. | ▼ | $48.40B |
| WAT Waters Corp /De/ | ▲ | $42.45B |
| ILMN Illumina, Inc. | ▶ | $40.95B |
| MTD Mettler Toledo International Inc/ | ▼ | $32.02B |
| RVTY Revvity, Inc. | ▼ | $17.30B |
| AVTR Avantor, Inc. | ▶ | $10.62B |
| BIO Bio-Rad Laboratories, Inc. | ▼ | $9.73B |
| TXG 10x Genomics, Inc. | ▲ | $9.35B |
| BRKR Bruker Corp | ▲ | $8.56B |
| ALMR Alamar Biosciences, Inc. | ▶ | $1.63B |
| CTKB Cytek Biosciences, Inc. | ▲ | $695M |
| PACB Pacific Biosciences Of California, Inc. | ▲ | $637M |
| MASS 908 Devices Inc. | ▲ | $500M |
| BFNH Bioforce Nanosciences Holdings, Inc. | ▼ | $275M |
| EYPT Eyepoint, Inc. | ▲ | $265M |
| NAUT Nautilus Biotechnology, Inc. | ▲ | $261M |
| QTRX Quanterix Corp | ▲ | $149M |
| SEER Seer, Inc. | ▶ | $119M |
| RPID Rapid Micro Biosystems, Inc. | ▲ | $44M |
| PRPO Precipio, Inc. | ▲ | $40M |
| HBIO Harvard Bioscience Inc | ▼ | $38M |
| BNGO Bionano Genomics, Inc. | ▲ | $16M |
| LCTC Lifeloc Technologies, Inc | ▲ | $11M |
| SCND Scientific Industries Inc | ▲ | $8M |
Where ASTC sits on the market map
Astrotech Corp (ASTC) stock news
Loading...
Astrotech Corp (ASTC) stock forecast FAQ
What is the Astrotech Corp (ASTC) stock forecast?
On Oct. 13, 2026, ASTC is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5379 stocks scored that day.
How accurate are Astrotech Corp stock predictions?
A per-ticker accuracy statistic for ASTC is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Astrotech Corp forecasts updated?
Astrotech Corp forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Astrotech Corp's industry peers?
25 issuers in our coverage, ASTC included, share the SEC industry code Laboratory Analytical Instruments. The largest are: Agilent Technologies, Inc. (A), Waters Corp /De/ (WAT), Illumina, Inc. (ILMN), Mettler Toledo International Inc/ (MTD), Revvity, Inc. (RVTY), Avantor, Inc. (AVTR).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.